We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Analysis of EMA approval of benralizumab for the treatment of eosinophilic esophagitis: phase 3 MESSINA data, comparison with dupilumab, risks and prospects. Read.
